Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D 2 partial agonists for the potential treatment of schizophrenia

• Published in: Bioorganic & medicinal chemistry letters Vol. 19; no. 19; pp. 5552 - 5555
• Main Authors: Rotella, David P., McFarlane, Geraldine R., Greenfield, Alexander, Grosanu, Cristina, Robichaud, Albert J., Denny, Rajiah Aldrin, Feenstra, Rolf W., Núñez-García, Sara, Reinders, Jan-Hendrik, Neut, Martina van der, McCreary, Andrew, Kruse, Chris G., Sullivan, Kelly, Pruthi, Farhana, Lai, Margaret, Zhang, Jean, Kowal, Dianne M., Carrick, Tikva, Grauer, Steven M., Navarra, Rachel L., Graf, Radka, Brennan, Julie, Marquis, Karen L., Pausch, Mark H.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.10.2009
• Subjects: Dopamine D 2 partial agonist; Dual-acting molecule; Schizophrenia; SRI; Schizophrenia; SRI; Dual-acting molecule; Dopamine D 2 partial agonist

A 5-fluoro-tetrahydrocarbazole serotonin reuptake inhibitor (SRI) building block was combined with a variety of linkers and dopamine D 2 receptor ligands in an attempt to identify potent D 2 partial agonist/SRI molecules for treatment of schizophrenia. This approach has the potential to treat a broa...